• Tempus AI recently announced a multi-year collaboration with Whitehawk Therapeutics focused on leveraging its real-world multimodal dataset to advance biomarker-driven oncology research and refine clinical trial design for emerging cancer therapies.
• This partnership highlights Tempus AI’s growing role in powering biotechnology innovation by applying de-identified data at scale to address unmet needs in high-impact cancer indications such as lung and gynecologic cancers.
• We'll explore how this new collaboration underscores Tempus AI's expanding influence in biopharma research and impacts its investment outlook.

These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Tempus AI Investment Narrative Recap

To be a Tempus AI shareholder, you need to believe that its real-world multimodal datasets and AI tools will become essential for precision oncology, helping drive partnerships with leading biopharma and foster recurring revenue growth. The latest multi-year collaboration with Whitehawk Therapeutics affirms this focus but does not materially shift the near-term catalyst, which remains the company’s ability to maintain rapid revenue growth while managing high R&D investments; the chief risk continues to be mounting competition and pricing pressure as industry rivals scale similar AI-enabled products.

Of Tempus AI’s recent announcements, the FDA clearance for its RNA-based Tempus xR IVD device in October stands out as particularly relevant. This not only showcases Tempus’ ability to secure regulatory approvals for innovative data-driven diagnostics but also supports its thesis of differentiated product offerings in a market increasingly focused on real-world data and AI for oncology drug development.

However, in contrast to the optimism around partnerships, investors should also be aware of growing competition and its potential to compress margins...

Tempus AI's narrative projects $2.1 billion in revenue and $295.0 million in earnings by 2028. This requires 29.7% yearly revenue growth and a $494.7 million earnings increase from current earnings of -$199.7 million.

Uncover how Tempus AI's forecasts yield a $77.55 fair value, a 13% downside to its current price.

Exploring Other Perspectives

Fair value estimates from 34 Simply Wall St Community members range from US$24.88 to US$283.91 per share, underscoring wide differences in outlook. While many believe in robust revenue growth drivers, the potential for margin compression from rising competition remains a key area to watch, so consider the diverse viewpoints before investing.

Explore 34 other fair value estimates on Tempus AI - why the stock might be worth less than half the current price!

Build Your Own Tempus AI Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Tempus AI research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 27 early-stage AI stocks could fund your retirement.
• We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.